세계 자연살해(NK) 세포 치료제 시장 규모는 2023년 28억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장 규모가 83억 달러에 달해 2024-2032년 사이 12.3%의 연평균 성장률(CAGR)을 기록할 것으로 예상했습니다. 노인 인구의 증가와 함께 암 신흥국 시장의 위험이 증가하고 있습니다.
주요 시장 촉진요인 : 운동 부족, 건강에 해로운 식습관, 대기오염의 증가, 암, 감염, 간질환 환자 증가로 인해 시장이 활성화되고 있습니다.
주요 시장 동향 : 위험과 독성을 최소화하는 종양 표적 항체 전략에 초점을 맞춘 임상 연구에 대한 광범위한 투자는 시장을 활성화하는 새로운 트렌드 중 하나입니다.
경쟁 상황 : 세계 시장에서 유명한 기업으로는 Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc.(Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc. 등이 있습니다.
지리적 동향 : 북미는 암 환자를 위한 정부 기관의 다양한 재정적 지원 제도가 있어 시장에서 뚜렷한 우위를 점하고 있습니다.
과제 및 기회 : 시장을 저해하는 과제 중 하나는 제조 공정의 어려움입니다. 이는 품질과 유효성을 보장하기 위해 확장 가능한 제조 방법을 개선함으로써 극복할 수 있습니다.
병용요법의 인기 상승
치료제 효과를 높이기 위해 NK세포 치료제를 다른 치료제와 병용하는 것이 널리 보급되고 있습니다. 예를 들어, Innate Pharma의 항 CD22 면역독소인 Lumoxiti는 CD22를 발현하는 암세포를 파괴하고 표적으로 삼기 위해 NK세포와 함께 모세포 백혈병에서 사용되고 있습니다. 또한, 이 접근법은 두 가지 치료법의 장점을 모두 활용합니다. 이 외에도 2024년 5월에는 자가면역질환, 암, 감염성 질환에 대한 혁신적인 세포 치료 플랫폼을 개발하는 바이오제약 기업 Coeptis Therapeutics Holdings, Inc.가 여러 항원을 표적으로 하는 SNAP-CAR NK 세포를 발표했습니다.
높아지는 규제 당국의 승인
NK 세포 생산의 신뢰성과 효율성 향상에 대한 정부 기관의 관심이 높아지는 것은 중요한 성장 촉진요인으로 작용하고 있습니다. 또한, 정부 기관은 실험실 연구를 실행 가능한 임상 치료로 전환하도록 장려하고 있으며, 이는 당분간 시장을 계속 활성화시킬 것으로 보입니다. 예를 들어, 2024년 4월, 차세대 NK세포 치료제 혁신 선도기업인 인제니움 테라퓨틱스(Ingenium Therapeutics)는 미국 식품의약국(FDA)으로부터 급성 골수성 백혈병(AML) 치료제로 희귀질환 치료제 지정을 받았습니다.
실시간 모니터링에 대한 수요 증가
NK 세포 치료제 개발에서 실시간 모니터링과 데이터 분석의 광범위한 통합은 치료제의 정확성과 환자 결과를 향상시키고 있습니다. 또한, Bio-Techne의 Ella 시스템과 같은 플랫폼은 NK 세포가 증식하는 동안 사이토카인 생산을 정확하게 모니터링하여 세포의 최적의 기능을 보장할 수 있습니다. 또한 실시간 분석을 통해 연구자들은 배양 조건을 동적으로 조정할 수 있어 생산된 NK 세포의 품질과 효능을 향상시킬 수 있습니다. 이는 시장에 긍정적인 영향을 미치고 있습니다.
The global natural killer cells therapeutics market size reached US$ 2.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.3 Billion by 2032, exhibiting a growth rate (CAGR) of 12.3% during 2024-2032. The rising risks of developing cancer, along with the expanding geriatric population, are propelling the market.
Major Market Drivers: The growing number of individuals with cancer, infectious diseases, and liver disorders, on account of the lack of physical activities, unhealthy dietary patterns, and the increasing air pollution levels, is catalyzing the market.
Key Market Trends: Extensive investments in clinical studies that focus on tumor-targeted antibody strategies to minimize risks and toxicities are among the emerging trends fueling the market.
Competitive Landscape: Some of the prominent companies in the global market include Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc. (Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited, and Ziopharm Oncology Inc., among many others.
Geographical Trends: North America exhibits a clear dominance in the market, owing to numerous financial schemes by government agencies across the region for cancer patients.
Challenges and Opportunities: One of the challenges hindering the market is the difficulty in manufacturing processes. This can be overcome by improving scalable production methods to ensure quality and efficacy.
Increasing Popularity of Combination Therapies
Combining NK cell therapies with other treatment modalities to enhance therapeutic efficacy is gaining extensive traction. For example, Innate Pharma's Lumoxiti, an anti-CD22 immunotoxin, is adopted in conjunction with NK cells to destroy and target CD22-expressing cancer cells in hairy cell leukemia. Moreover, this approach leverages the strengths of both therapies. Besides this, in May 2024, Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.
Growing Regulatory Approval
The rising focus among government agencies on enhancing the reliability and efficiency of NK cell production is acting as a significant growth-inducing factor. Furthermore, they are encouraging the translation of laboratory research into viable clinical therapies, which will continue to fuel the market over the foreseeable future. For example, in April 2024, Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
Rising Demand for Real-Time Monitoring
The widespread integration of real-time monitoring and data analytics into NK cell therapy development is enhancing treatment precision and patient outcomes. Moreover, platforms like Bio-Techne's Ella system enable precise monitoring of cytokine production during NK cell expansion, thereby ensuring optimal cell functionality. Real-time analytics also allow researchers to adjust culture conditions dynamically, which aids in improving the quality and effectiveness of the NK cells produced. This is positively influencing the market.
IMARC Group provides an analysis of the key trends in each segment of the market, along with the natural killer cells therapeutics market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on therapeutics, application, and end user.
NK Cell Therapies
NK Cell Directed Antibodies
Currently, NK cell directed antibodies hold the majority of the total market share
The report has provided a detailed breakup and analysis of the market based on the therapeutics. This includes NK cell therapies and NK cell directed antibodies. According to the report, NK cell directed antibodies represented the largest market segmentation.
NK cell directed antibodies target natural killer cells to enhance their ability to recognize and destroy cancer cells. For example, Affimed's AFM13, a bispecific NK cell engager, targets CD30 on cancer cells and CD16A on NK cells.
Cancer
Gastrointestinal Diseases
Immunoproliferative Disorders
Others
Cancer currently exhibits a clear dominance in the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes cancer, gastrointestinal diseases, immunoproliferative disorders, and others. According to the report, cancer represented the largest market segmentation.
The inflating need for effective cancer treatments drives the segment's growth. Recent product launches have underscored the potential of NK cell-based therapies in oncology. For instance, Fate Therapeutics' FT596 is an off-the-shelf, iPSC-derived NK cell therapy designed to target multiple cancer types, including B-cell malignancies.
Hospitals
Research Centers and Institutes
Others
Currently, research centers and institutes hold the majority of the total market share
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, research centers and institutes, and others. According to the report, research centers and institutes represented the largest market segmentation.
Research centers and institutes offer high-quality reagents and technologies that streamline NK cell research, which is increasing the natural killer cells therapeutics market share. For example, Bio-Techne's Cloudz Human NK Cell Expansion Kit allows researchers to expand NK cells ex vivo efficiently.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
Advancements in biotechnology and a strong focus on innovative cancer treatments are primarily catalyzing the market in North America. According to the IMARC, the United States cancer immunotherapy market size is projected to exhibit a growth rate (CAGR) of 10.90% during 2024-2032. Besides this, collaborations between biotech firms are strengthening the regional market.
Affimed GmbH
Bristol-Myers Squibb Company
Fate Therapeutics
Fortress Biotech Inc.
Glycostem Therapeutics
Innate Pharma S.A.
Kuur Therapeutics Inc. (Athenex Inc.)
Nkarta Inc.
Takeda Pharmaceutical Company Limited
Ziopharm Oncology Inc.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
May 2024: Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.
April 2024: Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
January 2024: Indapta Therapeutics, Inc., a privately held biotechnology company developing IDP-023, a natural killer (NK) cell therapeutics for the treatment of cancer, announced the treatment of the first patients in its Phase 1 trial in multiple myeloma and non-Hodgkin's lymphoma.